Cargando…

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

AIM: To evaluate new therapies for hepatitis C virus (HCV), data about real-world outcomes are needed. METHODS: Outcomes of 223 patients with genotype 1 HCV who started telaprevir- or boceprevir-based triple therapy (May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bichoupan, Kian, Tandon, Neeta, Martel-Laferriere, Valerie, Patel, Neal M, Sachs, David, Ng, Michel, Schonfeld, Emily A, Pappas, Alexis, Crismale, James, Stivala, Alicia, Khaitova, Viktoriya, Gardenier, Donald, Linderman, Michael, Olson, William, Perumalswami, Ponni V, Schiano, Thomas D, Odin, Joseph A, Liu, Lawrence U, Dieterich, Douglas T, Branch, Andrea D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395804/ https://www.ncbi.nlm.nih.gov/pubmed/28469811 http://dx.doi.org/10.4254/wjh.v9.i11.551

Ejemplares similares

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy
por: Martel-Laferrière, Valérie, et al.
Publicado: (2014)

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results
por: Bichoupan, Kian, et al.
Publicado: (2017)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus
por: Chekuri, Sweta, et al.
Publicado: (2016)

The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014)

Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis
por: Rocha, Chiara, et al.
Publicado: (2023)

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
por: Cooper, Curtis L, et al.
Publicado: (2012)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
por: Neukam, Karin, et al.
Publicado: (2015)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
por: Borba, Helena HL, et al.
Publicado: (2017)

Boceprevir
Publicado: (2012)

Management of Patients With Hepatitis C Virus, Monoclonal Gammopathy of Undetermined Significance, and Multiple Myeloma
por: Hannaford, Alisse, et al.
Publicado: (2017)

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
por: Coilly, Audrey, et al.
Publicado: (2015)

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study
por: Minguez, Carlos, et al.
Publicado: (2014)

Telaprevir
Publicado: (2012)

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
por: Xia, Zilei, et al.
Publicado: (2021)

Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study
por: Hershman, Melissa, et al.
Publicado: (2022)

COVID-19 in Liver Transplant Recipients: An Initial Experience From the US Epicenter
por: Lee, Brian T., et al.
Publicado: (2020)

The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
por: Kjellin, Midori, et al.
Publicado: (2018)

Automated phenotyping of patients with non-alcoholic fatty liver disease reveals clinically relevant disease subtypes
por: Vandromme, Maxence, et al.
Publicado: (2020)

Boceprevir-induced Herpes Zoster
por: Babalı, Ayşegul, et al.
Publicado: (2018)

IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders
por: Calisti, Giorgio, et al.
Publicado: (2015)

Telaprevir Experience From Turkey
por: Komur, Suheyla, et al.
Publicado: (2015)

Cutaneous Eruption due to Telaprevir
por: Falcão, Eduardo Mastrangelo Marinho, et al.
Publicado: (2015)

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies
por: Wedemeyer, Heiner, et al.
Publicado: (2016)

Comment to “Telaprevir Experience From Turkey”
por: Akar, Tarik, et al.
Publicado: (2015)

Innovations in Hepatitis C Screening and Treatment
por: Patel, Arpan A., et al.
Publicado: (2020)

Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study
por: Mangia, Alessandra, et al.
Publicado: (2017)

Boceprevir and personalized medicine in hepatitis C virus infection
por: Habersetzer, François, et al.
Publicado: (2012)

Acute pancreatitis associated with boceprevir: a case report
por: Bilar, Juliana Miguel, et al.
Publicado: (2014)

Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C
por: Perumalswami, Ponni V., et al.
Publicado: (2022)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Boceprevir: A new hope against hepatitis C virus
por: Brashier, Dick B. S., et al.
Publicado: (2012)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhi
por: Akar, Tarık, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h21ju9gpeah4vh7uo93ecjb8sv